论文部分内容阅读
对照临床实验证明:阿司匹林(ASA)与潘生丁合用可有效地减低做过腹股沟下及冠状动脉分流术的病人血管再度闭塞的发生率,推迟下肢动脉粥样硬化闭塞性疹病的发生以及减少心肌梗塞病人长期治疗后冠状动脉并发症的发生。然而联合用药在体内的抗血栓效果的药理学基础尚不清楚。在体外试验中,一般治疗浓度的潘生丁几乎没有抑制血小板聚集的作用,除非有红细胞存在。在动物的体内、体外试验中,潘生丁都能抑制血管内皮下膜血小板粘附。
Control clinical trials have shown that aspirin (ASA) in combination with dipyridamole can effectively reduce the incidence of recurrent vascular occlusion in patients undergoing groin and coronary bypass surgery, postponing the occurrence of atherosclerotic occlusive rash in lower extremities, and reducing myocardial infarction Long-term treatment of patients with coronary complications. However, the pharmacological basis of the anti-thrombotic effect of the combination in the body is not clear. In in vitro tests, the usual therapeutic concentrations of dipyridamole have virtually no effect on platelet aggregation unless erythrocytes are present. In animals, in vitro, dipyridamole can inhibit vascular endothelial subendothelial platelet adhesion.